Venus Medtech (Hangzhou) Inc. (HKG:2500)

Market Cap	919.58M -17.6%
Revenue (ttm)	341.39M -34.8%
Net Income	-453.68M
EPS	-1.04
Shares Out	437.90M
PE Ratio	n/a
Forward PE	203.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	603,000
Average Volume	1,215,853
Open	2.120
Previous Close	2.110
Day's Range	2.050 - 2.140
52-Week Range	1.770 - 5.470
Beta	1.27
RSI	46.59
Earnings Date	Mar 31, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Ve...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 605
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2500

Financial Performance

In 2025, Venus Medtech (Hangzhou)'s revenue was 306.79 million, a decrease of -34.84% compared to the previous year's 470.83 million. Losses were -407.69 million, -42.92% less than in 2024.

Financial numbers in CNY